Haploinsufficiency of the SHANK3 gene is causally linked to autism spectrum disorder (ASD), and ASD-associated genes are also enriched for chromatin remodelers. Here we found that brief treatment with romidepsin, a highly potent class I histone deacetylase (HDAC) inhibitor, alleviated social deficits in Shank3-deficient mice, which persisted for ~3 weeks. HDAC2 transcription was upregulated in these mice, and knockdown of HDAC2 in prefrontal cortex also rescued their social deficits. Nuclear localization of β-catenin, a Shank3-binding protein that regulates cell adhesion and transcription, was increased in Shank3-deficient mice, which induced HDAC2 upregulation and social deficits. At the downstream molecular level, romidepsin treatment elevated the expression and histone acetylation of Grin2a and actin-regulatory genes and restored NMDA-receptor function and actin filaments in Shank3-deficient mice. Taken together, these findings highlight an epigenetic mechanism underlying social deficits linked to Shank3 deficiency, which may suggest potential therapeutic strategies for ASD patients bearing SHANK3 mutations.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Silverman, J. L., Yang, M., Lord, C. & Crawley, J. N. Behavioural phenotyping assays for mouse models of autism. Nat. Rev. Neurosci. 11, 490–502 (2010).
Naisbitt, S. et al. Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron 23, 569–582 (1999).
Bonaglia, M. C. et al. Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am. J. Hum. Genet. 69, 261–268 (2001).
Durand, C. M. et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat. Genet. 39, 25–27 (2007).
Betancur, C. & Buxbaum, J. D. SHANK3 haploinsufficiency: a “common” but underdiagnosed highly penetrant monogenic cause of autism spectrum disorders. Mol. Autism 4, 17 (2013).
Leblond, C. S. et al. Meta-analysis of SHANK mutations in autism spectrum disorders: a gradient of severity in cognitive impairments. PLoS Genet. 10, e1004580 (2014).
Jiang, Y. H. & Ehlers, M. D. Modeling autism by SHANK gene mutations in mice. Neuron 78, 8–27 (2013).
Bozdagi, O. et al. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol. Autism 1, 15 (2010).
Peça, J. et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472, 437–442 (2011).
Wang, X. et al. Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum. Mol. Genet. 20, 3093–3108 (2011).
Kouser, M. et al. Loss of predominant Shank3 isoforms results in hippocampus-dependent impairments in behavior and synaptic transmission. J. Neurosci. 33, 18448–18468 (2013).
Duffney, L. J. et al. Autism-like deficits in Shank3-deficient mice are rescued by targeting actin regulators. Cell Rep. 11, 1400–1413 (2015).
Wang, X. et al. Altered mGluR5-Homer scaffolds and corticostriatal connectivity in a Shank3 complete knockout model of autism. Nat. Commun. 7, 11459 (2016).
Bidinosti, M. et al. CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency. Science 351, 1199–1203 (2016).
Speed, H. E. et al. Autism-associated insertion mutation (InsG) of SHANK3 exon 21 causes impaired synaptic transmission and behavioral deficits. J. Neurosci. 35, 9648–9665 (2015).
Jaramillo, T. C. et al. Altered striatal synaptic function and abnormal behaviour in Shank3 Exon4-9 deletion mouse model of autism. Autism Res. 9, 350–375 (2016).
Amodio, D. M. & Frith, C. D. Meeting of minds: the medial frontal cortex and social cognition. Nat. Rev. Neurosci. 7, 268–277 (2006).
Delorme, R. et al. Progress toward treatments for synaptic defects in autism. Nat. Med. 19, 685–694 (2013).
De Rubeis, S. et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 515, 209–215 (2014).
Chen, J. A., Peñagarikano, O., Belgard, T. G., Swarup, V. & Geschwind, D. H. The emerging picture of autism spectrum disorder: genetics and pathology. Annu. Rev. Pathol. 10, 111–144 (2015).
Crawley, J. N., Heyer, W. D. & LaSalle, J. M. Autism and cancer share risk genes, pathways, and drug targets. Trends Genet. 32, 139–146 (2016).
Guan, J. S. et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55–60 (2009).
Fischer, A., Sananbenesi, F., Mungenast, A. & Tsai, L. H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 31, 605–617 (2010).
Tsankova, N., Renthal, W., Kumar, A. & Nestler, E. J. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 8, 355–367 (2007).
Grayson, D. R., Kundakovic, M. & Sharma, R. P. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol. Pharmacol. 77, 126–135 (2010).
Klimek, V. M. et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res. 14, 826–832 (2008).
Piekarz, R. L. et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27, 5410–5417 (2009).
Fraczek, J., Vanhaecke, T. & Rogiers, V. Toxicological and metabolic considerations for histone deacetylase inhibitors. Expert Opin. Drug Metab. Toxicol. 9, 441–457 (2013).
McPheeters, M. L. et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 127, e1312–e1321 (2011).
Valenta, T., Hausmann, G. & Basler, K. The many faces and functions of β-catenin. EMBO J. 31, 2714–2736 (2012).
Murase, S., Mosser, E. & Schuman, E. M. Depolarization drives beta-Catenin into neuronal spines promoting changes in synaptic structure and function. Neuron 35, 91–105 (2002).
Yu, X. & Malenka, R. C. Beta-catenin is critical for dendritic morphogenesis. Nat. Neurosci. 6, 1169–1177 (2003).
Stoner, R. et al. Patches of disorganization in the neocortex of children with autism. N. Engl. J. Med. 370, 1209–1219 (2014).
Han, K. et al. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 503, 72–77 (2013).
Gilman, S. R. et al. Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron 70, 898–907 (2011).
Park, E. et al. The Shank family of postsynaptic density proteins interacts with and promotes synaptic accumulation of the beta PIX guanine nucleotide exchange factor for Rac1 and Cdc42. J. Biol. Chem. 278, 19220–19229 (2003).
Shcheglovitov, A. et al. SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature 503, 267–271 (2013).
Ebrahimi-Fakhari, D. & Sahin, M. Autism and the synapse: emerging mechanisms and mechanism-based therapies. Curr. Opin. Neurol. 28, 91–102 (2015).
Carlson, G. C. Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders. Pharmacol. Biochem. Behav. 100, 850–854 (2012).
Won, H. et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486, 261–265 (2012).
Chung, W. et al. Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression. Nat. Neurosci. 18, 435–443 (2015).
Duffney, L. J. et al. Shank3 deficiency induces NMDA receptor hypofunction via an actin-dependent mechanism. J. Neurosci. 33, 15767–15778 (2013).
Yuen, E. Y. et al. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 73, 962–977 (2012).
Wei, J. et al. Histone modification of Nedd4 ubiquitin ligase controls the loss of AMPA receptors and cognitive impairment induced by repeated stress. J. Neurosci. 36, 2119–2130 (2016).
Marcel, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17, 10–12 (2011).
Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
Anders, S., Pyl, P. T. & Huber, W. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
We thank X.Q. Chen for excellent technical support. This work was supported by the Nancy Lurie Marks Family Foundation and grants from the National Institutes of Health (MH112237, MH108842 and DA037618) to Z.Y. We also thank E.F. Trachtman and the Varanasi family for their donations.
The authors declare no competing financial interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Integrated supplementary information
Supplementary Figure 1 Romidepsin treatment leads to the sustained increase of social interaction time and social preference in young Shank3-deficient mice.
(a) Box plots showing the time spent investigating either the social (Soc) or nonsocial (NS) stimulus during sociability testing in young (5-6 weeks old) male Shank3+/ΔC mice with a brief treatment of romidepsin (RMD, 0.25 mg/kg, i.p., 3x, n=10) or saline (n=10) prior to and at different days after the injection. F3,36(treatment)=137.4, P<0.0001; +++ P<0.001, (Soc vs. NS), ** P<0.01, *** P<0.001 (saline vs. romidepsin), two-way rmANOVA. (b) Representative heat maps illustrating the time spent in different locations of the 3 chambers from the social preference tests in Shank3+/ΔC mice treated with RMD or saline. Locations of Soc and NS stimuli are labeled with the circles. (c) Bar graphs (mean ± SEM) and scatter plots showing the preference index of the sociability testing in adult (10-11 weeks old) Shank3+/ΔC (n=13) or WT (n=10) mice before and after romidepsin (0.25 mg/kg, i.p., 3x) treatment. F3,45=10.5, P<0.0001; * P<0.05,*** P<0.001, one-way ANOVA. (d) Bar graphs (mean ± SEM) and scatter plots showing the social preference index in Shank3+/ΔC mice (n=9, ~10 weeks old) before and after the second-round romidepsin treatment. F2,24=2.6, ^ P=0.09, one-way ANOVA.
Supplementary Figure 2 Current antipsychotics fail to increase social interaction time, while the pan-HDAC inhibitor trichostatin A (TSA) transiently improves social behaviors in Shank3-deficient mice.
(a–e) Box plots showing the time spent investigating either the social (Soc) or nonsocial (NS) stimulus during sociability testing in young (5-6 weeks old) male Shank3+/ΔC mice treated with fluoxetine (10 mg/kg, i.p., 14x, a, n=9), clozapine (5 mg/kg, i.p., 3x, b, n=11), valproic acid (VPA, 100 mg/kg, 3x, c, n=11), aripiprazole (1 mg/kg, 3x, d, n=9) or risperidone (0.1 mg/kg, 3x, e, n=10). In (c), F2,40(treatment)=0.71, P=0.5; +++ P<0.001 (Soc vs. NS), two-way rmANOVA. (f, g) Plots showing the preference index (f) and the time spent investigating either the Soc or NS stimulus (g) during sociability testing in Shank3+/ΔC mice before and after TSA treatment (0.5 mg/kg, i.p., 3x, n=8). In (f), F2,21=19.7, P<0.0001, one-way ANOVA. In (g), F2,28(treatment)=4.15, P=0.026; ++ P<0.01, +++ P<0.001 (Soc vs. NS), ### P<0.001 (pre- vs. post-injection), two-way rmANOVA. Inset (d,e,g): Representative heat maps illustrating the time spent in different locations of the 3 chambers (blue: 0 sec; red: ~20 sec) from the social preference tests of drug-treated Shank3+/ΔC mice.
(a) PCR images showing the ChIP (AcetyH3-occupied DNA), input (total DNA) and no-template control (NTC) signals with 3 primers (P1, P2, P3) designed against the promoter regions of Grin2a and Grin2b. The expected sizes of PCR products are labeled on the gels. The final primers used in the quantitative ChIP experiments are labeled by red circles. Top: diagram showing the primer locations on the 5′ upstream sequence of Grin2a and Grin2b. TSS, transcriptional start site. (b) The amplification curve and melt curve for AcetyH3-ChIP, input, and IgG control samples.
Supplementary Figure 4 Romidepsin treatment restores NMDAR synaptic function and global histone acetylation at 16–18 d, but not 30–32 d, postinjection.
(a,b) Input-output curves of NMDAR-EPSC in PFC pyramidal neurons from Shank3+/ΔC mice (Het, male) receiving treatment of romidepsin (RMD, i.p., 0.25 mg/kg, 3x) or saline. Recordings were performed at 16-18 days (a) or 30-32 days (b) post-injection. n=12 cells/3 mice each group. In (a), F1,22(treatment)=13.56, P=0.0013; * P<0.05, *** P<0.001, two-way rmANOVA. Data are mean ± SEM. Inset: representative NMDAR-EPSC traces. (c,d) Immunoblots and quantification analysis of the level of acetylated H3 and total H3 in the nuclear fraction of cortical slices from WT or Shank3+/ΔC mice (male) treated with saline or romidepsin at 16-18 days or 30-32 days post-injection. n=6 each group. In (d), F2,15=12.55, P=0.0006 (16-18 days); F2,15=27.72, P<0.0001 (30-32 days); ** P<0.01, *** P<0.001, ns, not significant, one-way ANOVA.
(a,b) PCR images showing the ChIP (AcetyH3-occupied DNA), input (total DNA) and no-template control (NTC) signals with 3 primers (P1, P2, P3) designed against the promoter regions of Arhgef7 and Limk1. The expected sizes of PCR products are labeled on the gels. Top Inset: diagram showing the primer locations on the 5′ upstream sequence of Arhgef7 and Limk1. TSS, transcriptional start site. Right Inset: The amplification curve and melt curve for AcetyH3-ChIP, input, and NTC samples. The final primers used in the quantitative ChIP experiments are labeled by red circles.
Supplementary Figure 6 Romidepsin treatment restores actin filaments in PFC of Shank3-deficient mice.
(a) High magnification confocal images (40x) of F-actin staining with phalloidin (co-stained with PSD-95 and DAPI) in PFC slices of WT vs. Shank3+/ΔC mice (5-6 weeks old, male) with i.p. injections of saline or romidepsin (0.25 mg/kg, 3x). (b) Quantification of PSD-95 levels (integrated densities) in PFC slices of different animal groups. n=27 images/3 mice each group.
Supplementary Figure 7 Romidepsin treatment has no effect on the expression of genes encoding NMDAR subunits or actin regulators in other brain regions and peripheral organs of Shank3-deficient mice.
(a,b) Quantitative real-time RT-PCR data on the mRNA level of Grin1, Grin2a, Grin2b, Arhgef7 and Limk1 in striatum, VTA, kidney and heart from WT or Shank3+/ΔC mice (5-6 weeks old, male) injected with saline or romidepsin (0.25 mg/kg, i.p., 3x). n=6 each group.
About this article
Cite this article
Qin, L., Ma, K., Wang, Z. et al. Social deficits in Shank3-deficient mouse models of autism are rescued by histone deacetylase (HDAC) inhibition. Nat Neurosci 21, 564–575 (2018). https://doi.org/10.1038/s41593-018-0110-8
Seminars in Pediatric Neurology (2020)
Truncating mutations in SHANK3 associated with global developmental delay interfere with nuclear β‐catenin signaling
Journal of Neurochemistry (2020)
A systems biology approach for defining the potential molecular framework of idiopathic hypereosinophilic syndrome with cutaneous involvement
Biochemical and Biophysical Research Communications (2020)
Schizophrenia Research (2020)
Current Opinion in Genetics & Development (2020)